Effects of long-term pioglitazone treatment on peripheral and central markers of aging.
BACKGROUND
Thiazolidinediones (TZDs) activate peroxisome proliferator-activated receptor gamma (PPARgamma) and are used clinically to help restore peripheral insulin sensitivity in Type 2 diabetes (T2DM). Interestingly, long-term treatment of mouse models of Alzheimer's disease (AD) with TZDs also has been shown to reduce several well-established brain biomarkers of AD including inflammation, oxidative stress and Abeta accumulation. While TZD's actions in AD models help to elucidate the mechanisms underlying their potentially beneficial effects in AD patients, little is known about the functional consequences of TZDs in animal models of normal aging. Because aging is a common risk factor for both AD and T2DM, we investigated whether the TZD, pioglitazone could alter brain aging under non-pathological conditions.


RESULTS
We used the F344 rat model of aging, and monitored behavioral, electrophysiological, and molecular variables to assess the effects of pioglitazone (PIO-Actos(R) a TZD) on several peripheral (blood and liver) and central (hippocampal) biomarkers of aging. Starting at 3 months or 17 months of age, male rats were treated for 4-5 months with either a control or a PIO-containing diet (final dose approximately 2.3 mg/kg body weight/day). A significant reduction in the Ca(2+)-dependent afterhyperpolarization was seen in the aged animals, with no significant change in long-term potentiation maintenance or learning and memory performance. Blood insulin levels were unchanged with age, but significantly reduced by PIO. Finally, a combination of microarray analyses on hippocampal tissue and serum-based multiplex cytokine assays revealed that age-dependent inflammatory increases were not reversed by PIO.


CONCLUSIONS
While current research efforts continue to identify the underlying processes responsible for the progressive decline in cognitive function seen during normal aging, available medical treatments are still very limited. Because TZDs have been shown to have benefits in age-related conditions such as T2DM and AD, our study was aimed at elucidating PIO's potentially beneficial actions in normal aging. Using a clinically-relevant dose and delivery method, long-term PIO treatment was able to blunt several indices of aging but apparently affected neither age-related cognitive decline nor peripheral/central age-related increases in inflammatory signaling.
Blalock
Eric M
EM
Department of Molecular and Biomedical Pharmacology, University of Kentucky Medical Center, Lexington, Kentucky, United States of America.
Phelps
Jeremiah T
JT
Pancani
Tristano
T
Searcy
James L
JL
Anderson
Katie L
KL
Gant
John C
JC
Popovic
Jelena
J
Avdiushko
Margarita G
MG
Cohen
Don A
DA
Chen
Kuey-Chu
KC
Porter
Nada M
NM
Thibault
Olivier
O
D000375:Aging / Q000187:drug effects*; D000544:Alzheimer Disease; D000818:Animals; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D001921:Brain / Q000502:physiology; D006624:Hippocampus; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007249:Inflammation; D007858:Learning / Q000187:drug effects; D008099:Liver; D017774:Long-Term Potentiation / Q000187:drug effects; D008297:Male; D008568:Memory / Q000187:drug effects; D000077205:Pioglitazone; D051381:Rats; D045162:Thiazolidinediones / Q000494:pharmacology*
D015415:Biomarkers; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone
Neurobiol Dis. 2004 Dec;17(3):500-6
15571985
J Neurochem. 2002 Aug;82(3):615-24
12153485
Brain Res. 2002 Jan 11;924(2):229-36
11750908
Learn Mem. 1996 Sep-Oct;3(2-3):124-37
10456083
Mol Cell Neurosci. 2005 Jan;28(1):42-54
15607940
Neurobiol Aging. 1988 Sep-Dec;9(5-6):581-90
3062469
FASEB J. 2005 Aug;19(10):1329-31
15919760
Circulation. 1999 Jun 8;99(22):2942-50
10359740
J Cereb Blood Flow Metab. 2007 Jul;27(7):1327-38
17213861
Diabetes Care. 2005 Jul;28(7):1547-54
15983299
Am J Physiol. 1995 Sep;269(3 Pt 1):E591-7
7573438
Pharmacogenomics J. 2006 Jul-Aug;6(4):246-54
16446752
Neurobiol Learn Mem. 2007 Jan;87(1):21-41
16829144
Am J Physiol. 1983 Sep;245(3):R364-71
6614206
Biochem Biophys Res Commun. 2009 Feb 6;379(2):406-10
19109927
Diabetes Metab Res Rev. 2000 Sep-Oct;16(5):308-15
11025555
J Neurosci. 2007 Mar 21;27(12):3098-110
17376971
Diabetes Care. 2007 Oct;30(10):2458-64
17595355
J Neurosci. 2005 Jun 22;25(25):5956-66
15976084
Exp Neurol. 2006 Jun;199(2):265-73
16515786
Chem Senses. 2002 Mar;27(3):299-306
11923192
Neurobiol Aging. 2001 Nov-Dec;22(6):937-44
11755002
Trends Pharmacol Sci. 2005 May;26(5):244-51
15860371
Neurosci Lett. 2008 Feb 27;432(3):198-201
18207323
Endocrinology. 2009 Aug;150(8):3457-64
19389833
Brain Behav Immun. 2009 Jan;23(1):46-54
18664380
Mol Cell Endocrinol. 2001 May 25;177(1-2):125-34
11377828
J Neuroimmunol. 1999 Dec;100(1-2):156-68
10695726
J Neurosci. 2000 Sep 15;20(18):6862-7
10995830
Eur J Pharmacol. 1998 Sep 18;357(2-3):243-50
9797043
Aging Cell. 2007 Jun;6(3):319-25
17517041
Diabetes Technol Ther. 2003;5(1):67-73
12725709
Neuroscience. 2005;130(3):685-96
15590152
Neuroreport. 2004 Oct 5;15(14):2255-9
15371745
CNS Drugs. 2003;17(1):27-45
12467491
Science. 1984 Nov 30;226(4678):1089-92
6494926
J Am Geriatr Soc. 1993 Dec;41(12):1305-12
8227912
Eur J Pharmacol. 2003 Jul 4;472(1-2):65-71
12860474
Br J Pharmacol. 1999 Oct;128(3):673-83
10516648
Neurobiol Aging. 2009 Jun;30(6):932-45
17950954
J Alzheimers Dis. 2005 Feb;7(1):63-80
15750215
CNS Drugs. 2008;22(1):1-14
18072811
Neurobiol Aging. 2005 Dec;26 Suppl 1:26-30
16236384
JAMA. 2007 Dec 12;298(22):2634-43
18073359
J Neuroinflammation. 2004 Jul 2;1(1):11
15285804
Science. 1996 May 17;272(5264):1017-20
8638124
J Neurophysiol. 1992 Dec;68(6):2100-9
1491260
Endocrinology. 1989 Nov;125(5):2341-9
2551647
J Neurosci. 2003 May 1;23(9):3807-19
12736351
Neurobiol Learn Mem. 2008 May;89(4):379-96
18234529
J Neurosci. 2008 Sep 10;28(37):9287-96
18784309
Clin Ther. 2002 Mar;24(3):378-96
11952022
Biotechniques. 2003 Feb;34(2):374-8
12613259
Science. 1989 Sep 29;245(4925):1505-9
2781293
Toxicol Appl Pharmacol. 1979 Apr;48(2):237-48
473173
Brain. 2005 Jun;128(Pt 6):1442-53
15817521
Drugs. 2000 Aug;60(2):333-43; discussion 344-5
10983737
Mol Cell Biol. 2000 Jul;20(13):4699-707
10848596
Nature. 1998 Jan 1;391(6662):79-82
9422508
Neurobiol Aging. 2007 Dec;28(12):1821-33
17052803
Behav Brain Res. 2001 Nov 1;125(1-2):279-84
11682119
J Neurochem. 2009 Jun;109(6):1800-11
19453298
Exp Cell Res. 2005 Mar 10;304(1):91-104
15707577
Behav Neurosci. 1993 Aug;107(4):618-26
8397866
Diabetes. 1997 Apr;46(4):659-64
9075808
Endocrinology. 1994 Jan;134(1):264-70
8275942
Neuroscience. 2003;118(2):577-83
12699792
Prog Neurobiol. 2003 Feb;69(3):143-79
12758108
Diabetologia. 2002 Apr;45(4):560-70
12032634
J Neurosci. 2002 Nov 15;22(22):9932-40
12427850
Nature. 1998 Jan 1;391(6662):82-6
9422509
Genome Biol. 2004;5(10):R80
15461798
J Biol Chem. 1997 Nov 7;272(45):28210-7
9353271
Annu Rev Med. 2002;53:409-35
11818483
J Am Geriatr Soc. 2009 Jan;57(1):177-9
19170800
Curr Opin Genet Dev. 2008 Oct;18(5):461-7
18782619
Nat Genet. 2000 Jul;25(3):294-7
10888876
Aging Cell. 2007 Jun;6(3):327-36
17517042
Am J Physiol. 1995 Oct;269(4 Pt 1):E759-65
7485492
Am J Cardiol. 2009 Jul 15;104(2):234-9
19576353
Pflugers Arch. 2004 Jul;448(4):395-401
15048576
Aging Cell. 2007 Jun;6(3):307-17
17465978
Neurobiol Aging. 1993 May-Jun;14(3):249-58
8321393
Life Sci. 1996;59(5-6):413-20
8761329
Arch Intern Med. 2000 Jan 24;160(2):174-80
10647755
Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2173-8
14769913
J Pain. 2008 Jul;9(7):639-49
18387855
Eur J Neurosci. 2006 Sep;24(6):1653-63
17004929
Neurobiol Aging. 2009 Dec;30(12):2053-64
18367293
Behav Neurosci. 1985 Dec;99(6):1040-8
3843538
J Cardiovasc Pharmacol. 2004 Jul;44(1):109-16
15175565
Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):182-8
16284192
J Neurochem. 2004 Jan;88(2):494-501
14690537
Arch Neurol. 2005 Oct;62(10):1539-44
16216936
Neuropharmacology. 2010 Feb;58(2):337-45
19891980
J Neurochem. 2007 Apr;101(1):41-56
17394460
Neurobiol Aging. 2010 Nov;31(11):1937-49
19070401
BMC Neurosci. 2007 Oct 08;8:84
17919343
EMBO J. 1996 Oct 1;15(19):5336-48
8895578
J Alzheimers Dis. 2006 Sep;10(1):89-109
16988486
Brain Res. 2006 Feb 16;1073-1074:460-9
16442504
Int Rev Neurobiol. 2002;51:289-324
12420363
J Neurophysiol. 1998 Jan;79(1):334-41
9425202
J Neurosci. 2006 Mar 29;26(13):3482-90
16571755
Front Biosci. 2008 Jan 01;13:1813-26
17981670
BMC Neurosci. 2009 Feb 19;10:12
19228403
Arzneimittelforschung. 1997 Jan;47(1):29-35
9037440
J Neurosci. 2003 Aug 20;23(20):7504-9
12930788
J Neurosci. 2009 Feb 11;29(6):1805-16
19211887
Genome Biol. 2007;8(9):R183
17784955
J Neurosci. 2000 Jan 15;20(2):558-67
10632585
Biol Psychiatry. 2005 Apr 15;57(8):885-94
15820709
Diabetes Metab Res Rev. 2002 Mar-Apr;18 Suppl 2:S10-5
11921433
Am J Geriatr Psychiatry. 2005 Nov;13(11):950-8
16286438
Brain Res. 1986 Mar 19;368(2):347-50
3697730
J Clin Exp Neuropsychol. 2004 Nov;26(8):1044-80
15590460
Pharmacology. 2005 Jan;73(1):15-22
15452359
J Neurosci. 1996 Sep 1;16(17):5536-46
8757265
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4668-73
10200320